Pneumococcal conjugate vaccine
Pneumococcal conjugate vaccine (PCV) is a class of vaccines designed to prevent disease caused by Streptococcus pneumoniae, a bacterium responsible for invasive pneumococcal disease, pneumonia, meningitis, and otitis media.
Pneumococcal conjugate vaccine (PCV) is a class of vaccines designed to prevent disease caused by Streptococcus pneumoniae, a bacterium responsible for invasive pneumococcal disease, pneumonia, meningitis, and otitis media. Unlike plain polysaccharide vaccines, pneumococcal conjugate vaccines link pneumococcal capsular polysaccharides to a carrier protein, a formulation intended to improve immune recognition and generate a more robust, T-cell-dependent antibody response, particularly in infants and young children.
Clinically, PCVs are used to reduce carriage of vaccine serotypes and to protect against pneumococcal disease across pediatric and adult populations. Different formulations cover different numbers of serotypes, including established products such as Pneumococcal Conjugate Vaccine 13 and newer higher-valency candidates such as V116. The immunologic readouts commonly used to evaluate these vaccines include serum IgG antibodies and functional activity such as opsonophagocytic activity.
Where the papers sit
10 papers from the last 6 months study pneumococcal conjugate vaccine directly · updated from PubMed 9 Nov 2026
Study type 4 clinical trials · 6 human data
Themes 3 themes
-
Pneumococcal Vaccine Policy Economics
Pneumococcal vaccination decisions are increasingly framed around population impact, cost-effectiveness, and protection in high-risk groups. Dynamic models project the health and economic effects of PCV20 in UK children and PCV21 in Swiss adults. Real-world Kenyan data examine protection against hypoxemia in childhood pneumonia, while Indonesian analyses prioritize vaccines for older adults. Results remain dependent on local disease burden, prices, and delivery assumptions.
4 papers · 40%
-
Expanded-Valency Vaccine Development
Pneumococcal vaccine development is moving toward broader serotype coverage in adults and higher-risk children. Studies assess the safety, tolerability, seroconversion, and immunogenicity of candidates including V116 and a 24-valent conjugate vaccine. Dynamic models examine the potential epidemiological impact of 20- and 21-valent products in adults. Serotype distribution, antimicrobial resistance, and existing immunization gaps continue to determine which added valencies are most useful.
4 papers · 40%
-
Infant Pneumococcal Vaccine Schedules
Infant vaccination is moving toward optimized one- and two-dose primary series with broader-valency products. Follow-up to age 5 years compares PCV10 and PCV13 schedules through immunogenicity and protection against invasive pneumococcal disease. Randomized multicentre studies are testing PCV15 and PCV20 against PCV13. The open question is how added serotype coverage balances immune responses, dosing burden, and clinical protection.
2 papers · 20%
Papers
The 10 papers from the last 6 months that study pneumococcal conjugate vaccine directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Pneumococcal Vaccine Policy Economics (4)
- Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18-64 years in Switzerland using PCV21. Journal of medical economics · 11 Sept 2026 PMID 42723339
- Priority setting for older adult vaccines in Indonesia: a multi-criteria decision analysis using SMART vaccines. Expert review of vaccines · 24 Aug 2026 PMID 42635066
- Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model. Expert review of vaccines · 1 Jul 2026 PMID 42384619
- Pneumococcal conjugate vaccine effectiveness against hypoxemia in children with suspected pneumonia in Kenya; analysis from a real-world sentinel surveillance platform. PloS one · 26 Jun 2026 PMID 42361069
Expanded-Valency Vaccine Development (4)
- Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trials. Expert review of vaccines · 22 Oct 2026 PMID 42908339
- A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13). Human vaccines & immunotherapeutics · 23 Jun 2026 PMID 42334402
- Invasive Pneumococcal Disease burden, clinical characteristics, serotypes' distribution, immunization status and antimicrobial resistance: Evidence from 12-year hospital-based surveillance and cost analysis. Human vaccines & immunotherapeutics · 26 May 2026 PMID 42189530
- Epidemiological impact of a 20- or 21-valent pneumococcal conjugate vaccine in the Japan adult population: insights from a dynamic transmission model. Expert review of vaccines · 22 May 2026 PMID 42169554
Infant Pneumococcal Vaccine Schedules (2)
- Open-label, randomised controlled, multicentre study evaluating higher valency pneumococcal vaccines (PCV15/PCV20) compared with PCV13 given in homologous schedules at 3 months and 12 months ('1+1' schedule) and 2 months, 4 months and 12 months ('2+1' schedule) in infants: protocol. BMJ open · 22 Sept 2026 PMID 42772879
- Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial. The Lancet. Child & adolescent health · 8 Sept 2026 PMID 42710524
By study type
Clinical trials (4)
- Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trials. Expert review of vaccines · 22 Oct 2026 PMID 42908339
- Open-label, randomised controlled, multicentre study evaluating higher valency pneumococcal vaccines (PCV15/PCV20) compared with PCV13 given in homologous schedules at 3 months and 12 months ('1+1' schedule) and 2 months, 4 months and 12 months ('2+1' schedule) in infants: protocol. BMJ open · 22 Sept 2026 PMID 42772879
- Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial. The Lancet. Child & adolescent health · 8 Sept 2026 PMID 42710524
- A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13). Human vaccines & immunotherapeutics · 23 Jun 2026 PMID 42334402
Human data, design not indexed (6)
- Cost-effectiveness analysis of pneumococcal vaccination of at-risk and high-risk adults aged 18-64 years in Switzerland using PCV21. Journal of medical economics · 11 Sept 2026 PMID 42723339
- Priority setting for older adult vaccines in Indonesia: a multi-criteria decision analysis using SMART vaccines. Expert review of vaccines · 24 Aug 2026 PMID 42635066
- Projected health and economic impact of PCV20 vaccination in UK children: a dynamic transmission model. Expert review of vaccines · 1 Jul 2026 PMID 42384619
- Pneumococcal conjugate vaccine effectiveness against hypoxemia in children with suspected pneumonia in Kenya; analysis from a real-world sentinel surveillance platform. PloS one · 26 Jun 2026 PMID 42361069
- Invasive Pneumococcal Disease burden, clinical characteristics, serotypes' distribution, immunization status and antimicrobial resistance: Evidence from 12-year hospital-based surveillance and cost analysis. Human vaccines & immunotherapeutics · 26 May 2026 PMID 42189530
- Epidemiological impact of a 20- or 21-valent pneumococcal conjugate vaccine in the Japan adult population: insights from a dynamic transmission model. Expert review of vaccines · 22 May 2026 PMID 42169554
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-24. Last written: 2026-07-29 by GPT. Drafted by language models from published abstracts; not medical advice.